Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINPROVE: Targeted Anti-cancer Drugs in Advanced Cancer
NCT05159245Phase 2Recruiting
- Sponsor
- Helsinki University Hospital
- Start
- Dec 2021
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of alectinib, cobimetinib, vismodegib, trastuzumab, pertuzumab and 10 more in cancer, solid tumor and hematologic malignancy (15 arms), sponsored by Helsinki University Hospital. Primary endpoint: Disease Control Rate at 16 weeks. Started Dec 2021; status: recruiting.
02
Drugs
03
Conditions
cancersolid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT05159245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159245.